Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 6/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.45 |
| ▸ | HTR2C | P28335 | 10/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5417427 | 0.98 | SLC18A3 (0.47) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL4706866 | 0.87 | HTR1A (0.58) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23215227 | 0.87 | QDPR (0.43) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL29768397 | 0.87 | QDPR (0.43) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5425882 | 0.85 | HTR1A (0.56) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10387633 | 0.84 | OPRL1 (0.49) | — | |
| SCHEMBL12290554 | 0.79 | SMN1; SMN2 (0.48) | HTR1AHTR2CHTR3AHTR2A | |
| SCHEMBL245508 | 0.78 | SLC6A2 (0.57) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL10693537 | 0.77 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL24770740 | 0.77 | HTR2C (0.46) | HTR1ASLC6A2SLC6A3HTR2CHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102285968-A | Preparation method of 3- [4- (2, 6-dichlorophenyl) -piperidine-1-methylene ] -2, 5-disubstituted indole | — | 2011-12-21 | — | — | CN | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| EP-1841755-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2007-10-10 | — | — | EP | disclosed |
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | GLAXOSMITHKLINE S.P.A. (IT) | 2007-08-23 | — | — | US | disclosed |
| US-7223867-B2 | Preparation of benzosuberonylpiperidine compounds | GLAXOSMITHKLINE S.P.A. (IT) | 2007-05-29 | — | — | US | disclosed |
| WO-2006070001-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676843-A1 | Substituted indole ligands for the ORL-1 receptor | NIKEM RESEARCH S.R.L. (IT) | 2006-07-05 | — | — | EP | disclosed |
| EP-1648881-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | GlaxoSmithKline S.p.A. (IT) | 2006-04-26 | — | — | EP | disclosed |
| US-20050059700-A1 | Preparation of benzosuberonylpiperidine compounds | GLAXOSMITHLINE S.P.A. (IT) | 2005-03-17 | — | — | US | disclosed |
| WO-2005005411-A1 | SUBSTITUTED INDOLE LIGANDS FOR THE ORL-1 RECEPTOR | GLAXOSMITHKLINE S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
| EP-1442017-A1 | PREPARATION OF BENZOSUBERONYLPIPERIDINE COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003040099-A1 | PREPARATION OF BENZOSUBERONYLPIPERIDINE COMPOUNDS | GLAXOSMITHKLINE S.P.A. (IT) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059700-A1 | Preparation of benzosuberonylpiperidine compounds | CYP2S1, COX6C, CYC1 | SLC18A3 4032/4885SIGMAR1 219/4885HTR1A 63/4885 |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | SLC18A3 353/4885SIGMAR1 20/4885HTR1A 14/4885 |
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | OGFRL1, OPRL1, ORMDL3 | SLC18A3 504/4885SIGMAR1 15/4885HTR1A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.